Description
YK-11 Powder — 1 Gram
YK-11 is a synthetic steroidal compound, derived from 5α-dihydrotestosterone (DHT), that has been characterized in cell studies as a partial agonist of the androgen receptor. Although it is commonly grouped with SARMs, its steroid backbone distinguishes it structurally from non-steroidal SARMs such as ostarine or ligandrol. This listing is a research-grade reference compound supplied in powder form for in vitro and laboratory investigation. Identity and purity are third-party verified and documented by a batch-dated, downloadable Certificate of Analysis.
- 98.76% purity (HPLC)
- Third-party verified
- 1,050 mg net
- Batch-dated COA
- UV-resistant foil pouch
Specifications & Documentation
- Compound
- YK-11 (YK11)
- Chemical Name
- (17α,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester
- CAS Number
- 1370003-76-1
- Molecular Formula
- C₂₅H₃₄O₆
- Molar Mass
- 430.54 g/mol
- Compound Class
- Steroidal androgen receptor partial agonist (commonly grouped with SARMs)
- WADA Classification
- Prohibited — Class S1.2 (Other Anabolic Agents)
- Form
- Crystalline powder
- Net Quantity
- 1,050 mg per pouch
- Verified Purity
- 98.76% by HPLC (COA dated 09/03/2025)
Third-Party Verification
Identity and purity are independently confirmed by MZ Biolabs (Tucson, AZ), a US DEA Schedule III licensed analytical facility (License RP0584676), using HPLC purity analysis and mass-spectrometry identity confirmation under Good Laboratory Practice (GLP) standards to support research reproducibility.
- Latest COA Date
- 09/03/2025
- Reported Purity
- 98.76%
- Methods
- HPLC–UV purity; MS identity confirmation
- Verifying Lab
- MZ Biolabs, Tucson, AZ (DEA Schedule III, RP0584676)
Current certificate of analysis for YK-11, dated 09/03/2025, issued by MZ Biolabs. Tap to view full size.
Open or download the current YK-11 COA · View the full COA archive →
Storage & Handling
Store in a cool, dry place away from direct sunlight to maximize shelf life. Supplied in a UV-resistant foil pouch to minimize photodegradation.
- Packaging
- UV-resistant sealed foil pouch
- Storage
- Cool, dry, dark; away from direct sunlight
- Handling
- Standard laboratory PPE and analytical-grade equipment
- Intended Use
- Laboratory and in vitro research only
Quality & Analytical Transparency
Independent analysis has repeatedly found that materials sold online as SARMs are frequently mislabeled or adulterated. A 2017 JAMA investigation that chemically analyzed products marketed as SARMs found that only a minority accurately matched their labeled contents, and a substantial share contained unapproved or entirely different substances.[6] Third-party testing is the control that distinguishes a documented reference compound from an unverified one.
Research Context
YK-11 was first described in 2011 by Japanese researchers as a partial agonist of the androgen receptor with gene-selective activity in MDA-MB-453 cells.[1] Subsequent cell studies reported that it induced follistatin expression during myogenic differentiation of C2C12 myoblasts[2] and influenced proliferation and differentiation markers in MC3T3-E1 osteoblastic cells.[3] It has also been examined in a mouse model of bacterial sepsis.[4] A 2024 rat study reported that YK-11 reached the hippocampus and was associated with increased pro-inflammatory cytokines, activation of apoptotic signaling, and altered memory consolidation.[5] Most published data on YK-11 come from cell culture, and its effects and safety in humans have not been established.
This material is supplied strictly as a reference compound to support such laboratory investigation. It is not a therapeutic product, dietary supplement, or sports supplement, and no clinical or performance outcomes are claimed or implied for any individual.
Compliance & Legal Status
YK-11 is an investigational compound that has not been approved by the U.S. Food and Drug Administration for human use. It is not a dietary supplement, and marketing it for human ingestion is unlawful. It is supplied exclusively for laboratory research purposes.
Scientific References
- Kanno Y, Hikosaka R, Zhang SY, et al. (17α,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester (YK11) is a partial agonist of the androgen receptor. Biol Pharm Bull. 2011;34(3):318–323.
- Kanno Y, Ota R, Someya K, et al. Selective androgen receptor modulator, YK11, regulates myogenic differentiation of C2C12 myoblasts by follistatin expression. Biol Pharm Bull. 2013;36(9):1460–1465.
- Yatsu T, Kusakabe T, Kato K, et al. Selective androgen receptor modulator, YK11, up-regulates osteoblastic proliferation and differentiation in MC3T3-E1 cells. Biol Pharm Bull. 2018;41(3):394–398.
- Lee SJ, Gharbi A, Shin JE, et al. Myostatin inhibitor YK11 as a preventative health supplement for bacterial sepsis. Biochem Biophys Res Commun. 2021;543:1–7.
- From gains to gaps? How selective androgen receptor modulator (SARM) YK11 impact hippocampal function: in silico, in vivo, and ex vivo perspectives. Chem Biol Interact. 2024;394:110971.
- Van Wagoner RM, Eichner A, Bhasin S, Deuster PA, Eichner D. Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet. JAMA. 2017;318(20):2004–2010.
- World Anti-Doping Agency. The Prohibited List, Section S1.2: Other Anabolic Agents. WADA.org.
Research Disclaimer
For laboratory research use only. This preparation is not approved by the FDA for human use. YK-11 is not a dietary or sports supplement and is not intended for human or animal consumption.
All products on this website are intended exclusively for research and development purposes. The statements herein have not been evaluated by the U.S. Food and Drug Administration. Neither the statements nor the products are intended to diagnose, treat, cure, or prevent any disease. Sports Technology Labs are chemical suppliers, not medical practitioners; our expertise is sourcing and quality control.




